---
layout: default
title: Brentuximab Vedotin
parent: 僅模型預測 (L5)
nav_order: 26
evidence_level: L5
indication_count: 10
---

# Brentuximab Vedotin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# BRENTUXIMAB VEDOTIN: Drug Repurposing Evaluation — No TxGNN Predictions Available

## One-Sentence Summary

BRENTUXIMAB VEDOTIN (DrugBank ID: DB08870) is currently not marketed in Taiwan and has no registered indications recorded in this Evidence Pack.
The TxGNN model has not generated any repurposing predictions for this drug in the current data pipeline run.
This evaluation **cannot be completed** until two critical data gaps — mechanism of action and package insert safety data — are resolved and the prediction pipeline is re-executed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Taiwan Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Data Gaps Blocking This Evaluation

Two unresolved data gaps are preventing a complete report:

| Gap ID | Severity | Missing Item | Impact | Remediation |
|--------|----------|-------------|--------|-------------|
| DG001 | 🔴 Blocking | TFDA package insert warnings & contraindications | Cannot proceed to safety screening (S1) | Download package insert PDF from TFDA website and parse |
| DG002 | 🟠 High | Mechanism of Action (MOA) | Cannot perform mechanistic plausibility analysis | Query DrugBank API for DB08870 |

Because `predicted_indications` is an empty array, none of the following standard sections — *Why is This Prediction Reasonable*, *Clinical Trial Evidence*, *Literature Evidence* — can be populated. They are omitted per report rules.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned zero predictions for BRENTUXIMAB VEDOTIN in this run, and one Blocking data gap (DG001: missing package insert safety data) prevents even a preliminary safety screen. No meaningful repurposing assessment can be issued without resolving these gaps first.

**To proceed, the following is needed:**

1. **Resolve DG001 (Blocking)** — Retrieve the TFDA package insert PDF for BRENTUXIMAB VEDOTIN and extract key warnings and contraindications; this is required before any safety evaluation can begin.
2. **Resolve DG002 (High)** — Query the DrugBank API (DB08870) to obtain the full mechanism of action, drug categories, and toxicity data; this enables mechanistic plausibility analysis and cytotoxicity assessment.
3. **Re-run TxGNN prediction pipeline** — Once drug-level data is complete, resubmit to the prediction model to generate candidate repurposing indications with confidence scores.
4. **Confirm original approved indications** — The `original_indications` array is currently empty; cross-reference with DrugBank or EMA/FDA label to populate this field before the next pipeline run.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

